This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other Neoplasms of Uncertain Behaviour of Lymphoid, Haematopoietic and Related Tissue, D47림프·조혈 및 관련 조직의 기타 행동양식 불명 신생물

Contents and key points
ItemDetails
A. Classification codesICD-10: D47 (neoplasms of uncertain behavior of lymphoid and hematopoietic tissue) — D47.0 mast cell neoplasms, D47.1 chronic myeloproliferative disease, D47.2 monoclonal gammopathy, D47.3 essential thrombocythemia, D47.4 myelofibrosis | Special Copayment Reduction: V193 (special copayment reduction for cancer: 5% copayment for 5 years from the registration date)
B. SynonymsMGUS, essential thrombocythemia (ET), mastocytosis, primary myelofibrosis (PMF), Waldenström macroglobulinemia (WM), chronic myeloproliferative neoplasm (MPN), urticaria pigmentosa
C. Clinical overviewD47 is a heterogeneous group of clonal neoplasms of the lymphocyte, monocyte, mast cell, and hematopoietic stem cell lineages that show biological behavior intermediate between benign and malignant. Some remain at an asymptomatic precursor stage, while some transform into progressive fibrosis or lymphoma/leukemia.
1. HistoryWM: first described by Waldenström in 1944. ET: first reported by Epstein and Goedel in 1934. Mastocytosis: urticaria pigmentosa described by Nettleship in 1869. PMF: myelofibrosis described in the late 19th century. MGUS: named by Kyle in 1978.
2. CausesMostly idiopathic. ET, PMF, and WM are related to advanced age and genetic predisposition. Radiation exposure and organic solvent exposure are associated with some MPNs.
3. GeneticsET: JAK2 V617F (~55%), CALR exon 9 insertion/deletion (~25%), MPL W515L/K (~5%). PMF: same driver mutations. SM: KIT D816V (>90%). WM: MYD88 L265P (>90%), CXCR4 mutations (~40%).
4. General epidemiologyMGUS: prevalence 3% at age 50 and above, 5% at 70 and above. ET: incidence about 1-3 per 100,000. PMF: about 0.5-1 per 100,000. SM: rare, but actual prevalence underestimated. WM: about 3 per 100,000.
5. PathophysiologyAcquisition of driver mutations → overactivation of JAK-STAT, PI3K-AKT, and BTK pathways → clonal proliferation and cytokine release → impaired hematopoiesis, fibrosis, excessive immunoglobulin secretion.
6. SymptomsMGUS is mostly asymptomatic. ET: thrombosis/bleeding, headache, dizziness. PMF: fatigue, night sweats, weight loss, abdominal distension (splenomegaly). SM: skin lesions, anaphylaxis, diarrhea. WM: fatigue/anemia, hyperviscosity syndrome (reduced vision, headache, bleeding).
7. SignsET: platelets ≥450×10⁹/L, splenomegaly. PMF: massive splenomegaly, transfusion dependence, leukoerythroblastosis. SM: Darier sign (wheal and erythema on rubbing the skin). WM: serum IgM ↑, anemia, findings of hyperviscosity.
8. ScreeningSerum protein electrophoresis (SPEP) to screen for MGUS; blood smear when blood cell abnormalities are present; JAK2 mutation testing for persistent thrombocytosis; tryptase measurement for skin lesions (urticaria pigmentosa).
9. DiagnosisBone marrow aspiration and biopsy (morphology, immunochemistry, molecular testing), quantitative serum immunoglobulins, SPEP/immunofixation electrophoresis, driver gene mutation analysis, flow cytometry, and abdominal CT/MRI (assessment of organ involvement) are used for integrated diagnosis.
10. TreatmentMGUS: observation. High-risk ET: hydroxyurea or peginterferon, low-dose aspirin. PMF: JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib), allogeneic hematopoietic stem cell transplantation. Advanced SM: avapritinib, midostaurin. WM: BTK inhibitors (zanubrutinib, ibrutinib), combined with CD20 monoclonal antibodies.
11. PrognosisMGUS: annual progression rate about 1%; ET: median survival 18-35 years or more; PMF: median survival from months to years depending on DIPSS. WM: median survival about 8-10 years; indolent SM: near-normal life expectancy.
12. PreventionMinimize exposure to hazardous substances; regular SPEP follow-up after MGUS is confirmed; management of cardiovascular risk factors in ET/PMF (thrombosis prevention); prescription of an epinephrine auto-injector in SM in preparation for anaphylactic crises.
13. ReferencesEssential thrombocythemia: 2024 update on diagnosis, risk stratification, and management … and 9 other papers

1. History

The ICD-10 D47 category encompasses a heterogeneous group of clonal neoplasms of lymphocyte, mast cell, and hematopoietic stem cell origin whose behavior is not clearly defined. Each disease within this category has its own independent history of description. Waldenström macroglobulinemia (WM) was first defined in 1944 when the Swedish physician Jan G. Waldenström reported the detection of high-molecular-weight monoclonal immunoglobulin M (IgM) together with serum hyperviscosity syndrome in two patients. Hyperviscosity-related neurological symptoms such as nasal bleeding, visual disturbance, and coma were prominent among the clinical findings at that time, and the scope of the definition was subsequently established as cases with bone marrow involvement by lymphoplasmacytic lymphoma (LPL) and IgM monoclonal gammopathy.

Essential thrombocythemia (ET) was first reported in 1934 by Epstein and Goedel as cases with persistent thrombocytosis accompanied by thrombosis and bleeding, and it was later also called "primary thrombocythemia." The concept was established in 1951 when Dameshek grouped ET together with polycythemia vera (PV), myelofibrosis, and chronic myeloid leukemia as "myeloproliferative diseases." The discovery of the JAK2 V617F mutation in 2005 was a landmark turning point confirming the common molecular basis of ET, PV, and PMF, and understanding deepened further in 2013 when CALR (calreticulin) gene exon 9 mutations were discovered in JAK2-negative ET and PMF.

The origin of mastocytosis is the description of "urticaria pigmentosa" by the British ophthalmologist Nettleship in 1869, and in 1936 Ellis first systematically reported organ involvement by mast cells. In the 1991 WHO classification, mastocytosis began to be classified as an independent disease, and the discovery in 1993 of an activating mutation of the KIT receptor tyrosine kinase (KIT D816V) made a molecular understanding possible. The clinical concept of monoclonal gammopathy (MGUS) was established in 1978 when Robert Kyle named the state in which a serum monoclonal immunoglobulin is detected but clear diagnostic criteria for multiple myeloma, WM, amyloidosis, and the like are not met "monoclonal gammopathy of undetermined significance." For primary myelofibrosis (PMF), fibrotic findings of the bone marrow were first described by German pathologists in the late 19th century, but molecular classification became possible after 2005 as the JAK2, CALR, and MPL driver mutations were revealed.


2. Causes

Most diseases within the D47 category are idiopathic clonal neoplasms whose causes have not been clearly identified. However, associations with various environmental and genetic risk factors have been revealed through research. Age is the most consistent risk factor across this disease group, and the incidence of most subtypes rises sharply after age 50. MGUS is found in about 3% of adults aged 50 and older and about 5% of those aged 70 and older, suggesting that it lies on a continuum of age-related clonal hematopoietic abnormalities.

There is evidence that radiation and chemical exposures are related to the development of some myeloproliferative neoplasms (MPN). A significantly increased risk of MPN has been reported in atomic bomb survivor cohorts and in populations exposed to Chernobyl radiation. Exposure to benzene and other organic solvents is also recognized as a risk factor for myeloproliferative diseases, and epidemiological data have accumulated showing high incidences of MPN and MDS in benzene-exposed workers. Smoking is positively correlated with the size of JAK2 V617F mutant clones, and an association particularly with the development of PV has been reported.

Immune dysfunction and chronic inflammation may also contribute to the pathogenesis of lymphoplasmacytic neoplasms such as WM. Chronic infections with hepatitis B virus, hepatitis C virus, and Helicobacter pylori are related to the development of mucosa-associated lymphoid tissue (MALT) lymphoma, but their direct association with WM is limited. Regarding family history, having a first-degree relative with WM or another B-cell neoplasm is known to increase the risk of WM about 3-5-fold, suggesting that genetic predisposition plays an important role. In mastocytosis, somatic mutations of the KIT receptor are the main cause of almost all adult-type systemic mastocytosis, and very rarely familial mastocytosis due to germline KIT mutations has also been reported. ET and PMF occur sporadically even without a specific predisposition, and hereditary ET rarely arises from germline mutations of the MPL or THPO genes.


3. Genetics

The diseases within the D47 category either share or independently carry characteristic somatic driver mutations. In essential thrombocythemia and primary myelofibrosis, three main driver mutations exist in a mutually exclusive manner. The JAK2 V617F mutation is found in about 55% of ET and about 60% of PMF; it substitutes valine for phenylalanine at residue 617 in the autoinhibitory domain (pseudokinase domain, JH2) of the JAK2 tyrosine kinase, causing persistent STAT5 and STAT3 activation. CALR (calreticulin) exon 9 insertion/deletion mutations are found in about 25% of ET and about 25-30% of PMF and are divided into type 1 (52 bp deletion) and type 2 (5 bp insertion). The mutant CALR protein binds abnormally to the extracellular domain of MPL (the thrombopoietin receptor), causing ligand-independent MPL activation. MPL W515L/K mutations are found in about 5-10% of ET and PMF and constitutively activate the thrombopoietin receptor. Triple-negative ET and PMF, negative for all three driver mutations, account for about 10-15% and have a poor prognosis.

In addition to driver mutations, non-driver high-risk mutations such as ASXL1, EZH2, IDH1/2, SRSF2, and U2AF1 additionally appear in PMF and affect prognosis and treatment response. In systemic mastocytosis, the KIT D816V mutation is the core pathogenic mutation found in more than 90% of adult-type SM, in which aspartic acid at residue 816 within the activation loop of the KIT receptor is substituted with valine. This causes persistent ligand (stem cell factor, SCF)-independent dimerization and phosphorylation of the KIT receptor, resulting in clonal proliferation of mast cells. In advanced SM (ASM, MCL), TET2, ASXL1, RUNX1, and SF3B1 mutations are additionally frequently present and worsen the prognosis.

In Waldenström macroglobulinemia, the MYD88 L265P mutation is the most characteristic molecular marker, found in about 90-95% of patients. MYD88 is an innate immune signal transducer; with the L265P mutation it spontaneously forms dimers and activates the NF-κB pathway via IRAK4 and IRAK1 and BTK (Bruton tyrosine kinase). CXCR4 mutations (mainly S338X frameshift) are co-expressed with MYD88 mutations in about 30-40% of WM patients and are known to regulate the bone marrow homing pathway and reduce response to BTK inhibitor therapy. MGUS has a low somatic mutation burden; MYD88 L265P is found in about 50% of IgM MGUS and rarely in non-IgM MGUS. Genetic abnormalities associated with progression from MGUS to multiple myeloma include del(17p) (TP53), amp(1q), and RAS pathway mutations.


4. General epidemiology

The epidemiological characteristics of each disease within the D47 category differ considerably. MGUS is the most common of these, found in about 3% of the population aged 50 and older, about 5% of those aged 70 and older, and about 8% of those aged 85 and older. In the long-term Olmsted County cohort in the United States (Kyle et al., 2006), the general population-based prevalence of MGUS was confirmed to be 3.2% in those aged 50 and older. Prevalence is higher in men (about 4%) than in women (about 2.7%), and it is notable that prevalence in African Americans is about twice that in white people. East Asians, including Koreans, tend to have a lower MGUS prevalence than Western white populations, but large-scale population-based data in Korea are limited.

The annual incidence of essential thrombocythemia is reported to be about 1-3 per 100,000, and the median age at diagnosis is about 60 years, but it shows a bimodal distribution (young women in their 30s-40s and older adults aged 60 and above). ET occurs at a slightly higher frequency in women. The annual incidence of primary myelofibrosis is about 0.5-1 per 100,000, and the median age at diagnosis is about 65 years, older than for ET. PMF incidence is similar in men and women or slightly higher in men. According to Health Insurance Review & Assessment Service (HIRA) data, the overall prevalence of MPN in Korea is estimated at about 5-10 per 100,000 population.

The exact incidence of systemic mastocytosis is underestimated, but it is estimated at about 0.3-1 per 100,000 per year. Indolent systemic mastocytosis (indolent SM, ISM) is the most common form (about 60-70%), and advanced SM (aggressive SM, ASM; mast cell leukemia, MCL) is relatively rare. The annual incidence of Waldenström macroglobulinemia is about 3 per 100,000 (about 5 in men, about 2.5 in women), and the median age at diagnosis is about 65-70 years. WM accounts for about 1-2% of all non-Hodgkin lymphomas. WM is known to have a somewhat lower incidence in Asians than in Western populations, but Korea-specific epidemiological data are not yet sufficient. Because the risk of WM is markedly higher with a family history, the importance of genetic predisposition is emphasized.


5. Pathophysiology

The pathogenesis of the D47 category diseases follows a common paradigm: acquisition of driver mutations in clonal hematopoietic cells, overactivation of intracellular signaling pathways, and interaction with the microenvironment. Overactivation of the JAK-STAT pathway is the core pathogenic mechanism of ET and PMF. JAK2 V617F, mutant CALR protein, and MPL W515 mutations all ultimately constitutively activate the JAK2-STAT5 pathway, causing thrombopoietin- and erythropoietin-independent proliferation of hematopoietic stem cells. Mutant CALR protein is a form in which the negatively charged C-terminal sequence of the endoplasmic reticulum (ER)-resident protein CALR is removed and a new positively charged C-terminus is inserted, inducing abnormal receptor activation through electrostatic interaction with the N-glycans of the MPL extracellular domain. Fibrosis in PMF results from overproduction of TGF-β, PDGF, VEGF, and bFGF induced by JAK-STAT overactivation and reactive collagen secretion by stromal cells and megakaryocytes.

KIT D816V signaling is central to the development of mastocytosis. KIT is a type III receptor tyrosine kinase with SCF as its ligand; normally, dimerization and downstream signaling (PI3K-AKT, MAPK-ERK, JAK-STAT pathways) occur after SCF binding. The D816V mutation locks the activation loop of the kinase domain in a permanently open conformation, causing SCF-independent activation and also conferring resistance to standard KIT inhibitors (imatinib). In advanced SM, additional somatic mutations accumulate besides KIT D816V, leading to more aggressive clonal evolution.

Activation of the MYD88-BTK pathway is the core pathophysiologic mechanism of WM. The mutant MYD88 L265P protein spontaneously forms dimers that recruit and phosphorylate IRAK4 and IRAK1, leading to constitutive activation of the NF-κB pathway. In this process, BTK (Bruton tyrosine kinase) is also recruited to the MYD88-IRAK4 complex and contributes to activation of the PI3K-AKT and MAPK pathways. Concomitant CXCR4 mutations enhance SDF-1α/CXCL12-mediated cell homing and survival signaling, reducing the response to BTK inhibitors. In MGUS, a monoclonal plasma cell or B-cell clone is basically present at a low burden, but as additional chromosomal instability and microenvironmental changes accumulate, the proliferating cell fraction increases and immunoglobulin is oversecreted, resulting in damage to target organs (kidney, nerves, heart, etc.).


6. Symptoms

Diseases in the D47 category show a diverse spectrum of clinical symptoms. MGUS by definition is not accompanied by clinical symptoms, and a serum monoclonal protein band is discovered incidentally on blood tests performed for health checkups or evaluation of other diseases. However, IgM MGUS may be accompanied by demyelinating neuropathy, and rarely cold agglutinin-associated hemolytic anemia may occur.

The main symptoms of essential thrombocythemia are thrombosis and bleeding. Both arterial thrombosis (stroke, transient ischemic attack, myocardial infarction) and venous thrombosis (deep vein thrombosis, pulmonary embolism, splanchnic vein thrombosis) can occur. A bleeding tendency due to platelet dysfunction (epistaxis, gastrointestinal bleeding) also occurs. Characteristic symptoms of microvascular thrombosis include headache, dizziness, visual disturbances, and burning of the hands and feet (erythromelalgia). Erythromelalgia is characterized by paroxysmal burning pain, erythema and warmth of the distal extremities that respond well to low-dose aspirin, and is a major microvascular symptom in ET and PV.

In primary myelofibrosis, extramedullary hematopoiesis due to progressive bone marrow fibrosis is the main clinical feature. Abdominal distension, early satiety, and left upper quadrant pain due to splenomegaly are common. Constitutional symptoms include severe fatigue, night sweats, fever, and weight loss, which are attributed to chronic cytokine (TNF-α, IL-1β, IL-6) release. Anemia-related symptoms (palpitations, exertional dyspnea) and a bleeding tendency due to thrombocytopenia are also important symptoms. In systemic mastocytosis, anaphylaxis and allergy-like symptoms (urticaria, flushing, abdominal pain, diarrhea) caused by histamine release are typical, and gastrointestinal symptoms (nausea, vomiting, increased gastric acidity) due to chronic release of mast cell mediators also occur. In the skeletal system, osteoporosis or osteopenia is frequent, and in advanced SM, symptoms of organ damage (hepatosplenomegaly, ascites) are added.

The most characteristic symptom of Waldenström macroglobulinemia is hyperviscosity syndrome caused by high IgM concentrations. Visual impairment, headache, dizziness, tinnitus, confusion, and coma may occur, and sausage-shaped retinal vein dilation on funduscopic examination is typical. Peripheral neuropathy (IgM-related peripheral neuropathy, MGUS-PN) occurs in about 20–25% of patients and usually begins with symmetric sensory abnormalities of the lower extremities. Fatigue and lethargy due to anemia (mainly IgM-mediated immune hemolysis or bone marrow infiltration) are among the most common presenting symptoms.


7. Signs

Physical examination findings of diseases in the D47 category reflect the characteristics of each disease. In principle, MGUS has no specific findings on physical examination. Obesity or signs of peripheral neuropathy may be present in some patients but are not specific to MGUS itself.

In essential thrombocythemia, splenomegaly is palpable in about 40–50% of patients at the initial visit, and its frequency increases with progression. Hepatomegaly is less common than splenomegaly. During erythromelalgia attacks, erythema, warmth, and tenderness of the distal extremities are observed. With severe thrombocytosis (generally platelets ≥ 1,500×10⁹/L), the bleeding tendency increases due to a decrease in acquired von Willebrand factor (vWF). On peripheral blood tests the platelet count is 450×10⁹/L or higher, and atypical giant platelets and platelet clumps are observed on the smear.

In primary myelofibrosis, massive splenomegaly is the most prominent sign, and on palpation a spleen markedly protruding below the left costal margin is identified. A friction rub may be auscultated in splenic infarction. The peripheral blood smear shows a characteristic leukoerythroblastic picture with teardrop red cells (dacryocytes, teardrop cells), nucleated RBCs, and immature granulocytes. Subcutaneous extramedullary hematopoiesis nodules may rarely be palpable in the skin.

Characteristic skin signs of systemic mastocytosis are urticaria pigmentosa, yellowish-brown or brown macules and papules. Darier's sign is a mast cell degranulation reaction in which a wheal and flare form within minutes after the skin lesion is scratched with a finger, and is the classic clinical sign of mastocytosis. Hepatomegaly and splenomegaly may appear as signs of organ involvement. A serum tryptase level of 20 ng/mL or higher is a minor criterion for systemic mastocytosis and is used as a surrogate marker of bone marrow mast cell infiltration.

In Waldenström macroglobulinemia, the triad of lymphadenopathy, splenomegaly, and hepatomegaly on physical examination is typical. On funduscopic examination, sausage-shaped dilation of the retinal veins, retinal hemorrhages, and optic disc edema are objective evidence of hyperviscosity syndrome. Signs of peripheral neuropathy (loss of vibration sense, loss of tendon reflexes) may be found in the lower extremities. With concomitant cryoglobulinemia, Raynaud's phenomenon, skin ulcers, and acrocyanosis may occur.


8. Screening

Systematic population-based screening for diseases in the D47 category is currently not established as standard. However, selective evaluation of specific patient groups is recommended in the clinical context. Regarding MGUS screening, serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) are recommended in patients with peripheral neuropathy of unknown cause, renal dysfunction, or osteoporosis. Adding the serum free light chain (FLC) assay helps with MGUS type classification and progression risk stratification. Screening with SPEP in high-risk groups aged 50 years or older (African ancestry, positive family history, obesity) is under discussion, but it is not yet recommended as a screening test in the general population.

Regarding myeloproliferative neoplasm (MPN) screening, when the platelet count persistently remains at 450×10⁹/L or higher on repeated peripheral blood tests, it is recommended to first perform JAK2 V617F mutation testing after excluding causes of reactive thrombocytosis (iron deficiency, infection, inflammation). If JAK2 is negative, CALR exon 9 mutation and MPL W515 mutation tests are performed sequentially. MPN screening is also considered in patients with unexplained splenomegaly or persistent leukocytosis. For mastocytosis screening, measurement of serum baseline tryptase is recommended in patients with recurrent anaphylaxis (especially after bee stings) or unexplained urticaria pigmentosa skin lesions. If baseline tryptase is 20 ng/mL or higher, bone marrow biopsy should be considered to exclude systemic mastocytosis. For WM screening, IgM level monitoring and SPEP may be performed in high-risk patients with a family history, but there are no formal screening guidelines for the general population.


9. Diagnosis

Confirmation of diseases in the D47 category requires a multidisciplinary approach integrating clinical findings, blood tests, bone marrow pathology, and molecular testing. The diagnosis of MGUS is made by confirming a serum monoclonal protein level < 3 g/dL (any of IgG, IgA, or IgM), a bone marrow plasma cell proportion < 10%, and that the diagnostic criteria for related hematologic malignancies such as multiple myeloma, WM, and primary amyloidosis are not met (2003 International Myeloma Working Group consensus criteria). SPEP, IFE, serum immunoglobulin quantification, and the FLC ratio are the basic tests, and in non-IgM MGUS, lytic bone lesions are excluded with a skeletal survey or whole-body low-dose CT.

The diagnosis of essential thrombocythemia follows the 2016 WHO criteria. The major criteria include (1) platelet count ≥ 450×10⁹/L, (2) bone marrow biopsy findings (increased megakaryocyte number and size, abnormal nuclear lobulation maturation, no clear fibrosis, left shift, or erythroid abnormality), (3) exclusion of PV, PMF, BCR-ABL1-positive CML, MDS, etc., and (4) identification of one or more of the JAK2 V617F, CALR exon 9, or MPL W515 mutations. In triple-negative ET, the minor criterion (identification of a clonal marker or exclusion of reactive thrombocytosis) must be met. Clusters of atypical megakaryocytes (staghorn-like, stag-horn nuclei) on bone marrow biopsy are a characteristic finding of ET.

The diagnosis of systemic mastocytosis is confirmed according to the WHO criteria when the major criterion (dense mast cell infiltrates in the bone marrow or other extracutaneous organs, aggregates of ≥15 mast cells) plus 1 of 3 minor criteria, or 3 minor criteria, are met. The minor criteria are (1) atypical morphology of polygonal/spindle-shaped mast cells, (2) detection of a KIT codon 816 point mutation (including D816V), (3) coexpression of CD25 or CD2 together with CD117, and (4) serum baseline tryptase > 20 ng/mL. Bone marrow trephine biopsy is central to the diagnosis, and high-sensitivity KIT D816V analysis (NGS or allele-specific PCR) is mandatory. CD117 (KIT), tryptase, CD25, CD2, and CD30 are checked as immunohistochemical markers of mast cells.

The diagnosis of Waldenström macroglobulinemia is established by (1) IgM monoclonal gammopathy (regardless of concentration), (2) histologic confirmation of bone marrow infiltration by lymphoplasmacytic lymphoma (LPL) on bone marrow biopsy, and (3) detection of the MYD88 L265P mutation (diagnostic aid). An IgM monoclonal peak is identified on SPEP, and the quantitative serum IgM level is evaluated. On bone marrow flow cytometry, a lymphoplasmacytic phenotype of surface IgM+, CD19+, CD20+, CD138dim/- is characteristic. Because CXCR4 mutation testing helps in treatment selection, it is included in the baseline workup when possible. Evaluation of lymph node, spleen, and liver involvement by abdominal CT and serum viscosity testing provide complementary diagnostic information.


10. Treatment

Treatment of MGUS is, in principle, observation (watch-and-wait). IgG MGUS (M protein < 1.5 g/dL, IgG subtype, normal FLC ratio — low-risk group) is first followed up after 3–6 months and then evaluated once a year or when symptoms change. For IgM MGUS and intermediate- to high-risk MGUS, more frequent follow-up at 6–12-month intervals is recommended. There is currently no proven preventive treatment that prevents the progression of MGUS to multiple myeloma or WM, and validation through clinical trials is ongoing.

Treatment of essential thrombocythemia is individualized according to thrombotic risk. In low-risk ET (under 60 years, no history of thrombosis), low-dose aspirin (75–100 mg/day) is recommended, and twice-daily dosing is recommended when the JAK2 V617F mutation is present (to suppress bilateral platelet activation). In high-risk ET (age 60 or older, or history of thrombosis, or age 60 or older + JAK2 V617F), cytoreductive therapy is started. For first-line cytoreductive therapy, hydroxyurea and pegylated interferon α-2a are equivalent first-line choices. Peginterferon is preferred especially in women of childbearing age or in patients resistant or intolerant to hydroxyurea. As second-line therapy, busulfan can be used in elderly patients. Anagrelide may be used as a second- or third-line option in European guidelines in cases of hydroxyurea resistance or intolerance.

Treatment of primary myelofibrosis is determined based on IPSS or DIPSS-plus risk classification. In low-risk PMF without symptoms, observation is possible. For anemia, erythropoiesis-stimulating agents, danazol, corticosteroids, and thalidomide/lenalidomide combinations may be tried. JAK inhibitors are the key treatment for symptomatic PMF, and the currently FDA-approved agents are ruxolitinib (2011), fedratinib (2019), pacritinib (2022—patients with platelets < 50×10⁹/L), and momelotinib (2023—patients with anemia). Ruxolitinib is the first-line standard treatment with proven efficacy in reducing spleen volume and improving symptoms, but anemia and thrombocytopenia as adverse effects are a problem. Momelotinib has a unique anemia-improving effect through hepcidin suppression via ACVR1 (ALK2) inhibition, and can be considered as a preferred choice in PMF patients with anemia. Allogeneic hematopoietic stem cell transplantation (alloSCT) is currently the only potentially curative treatment for PMF and is considered in patients aged 65 or younger with intermediate-high risk or higher.

Treatment of systemic mastocytosis differs according to disease subtype. In indolent SM, symptom management is key, and histamine H1 and H2 blockers, mast cell stabilizers (cromolyn sodium), and antileukotrienes are used. An epinephrine autoinjector should be prescribed to all patients at risk of anaphylaxis. In advanced SM (ASM, MCL), avapritinib, a highly selective KIT D816V inhibitor, received FDA approval in 2021 and achieved an overall response rate of 75% and a complete response rate of 19% in the EXPLORER trial. Midostaurin, a multikinase inhibitor, was the first approved treatment for advanced SM (2017), but because of its low selectivity it is tending to be replaced by avapritinib. Bone marrow transplantation is selectively considered in ASM and MCL.

Treatment of Waldenström macroglobulinemia is started in symptomatic patients (IgM-related peripheral neuropathy, hyperviscosity syndrome, cytopenias, symptoms of tissue infiltration). The current standard treatment is a BTK inhibitor alone or in combination with an anti-CD20 monoclonal antibody. Zanubrutinib is more selective than ibrutinib and has fewer off-target adverse effects such as atrial fibrillation and bleeding, and in the ASPEN trial showed a superior best response rate compared with ibrutinib. In MYD88 wild-type WM, zanubrutinib shows a clear advantage over ibrutinib. In patients with CXCR4 mutations as well, zanubrutinib shows a better response than ibrutinib. Combination chemotherapy with rituximab + bendamustine or rituximab + cyclophosphamide + dexamethasone (DRC) is also effective, but its use is gradually decreasing in the era of BTK inhibitors. When hyperviscosity syndrome presents acutely, plasmapheresis is performed immediately to rapidly lower the serum IgM level. Autologous hematopoietic stem cell transplantation may be considered in certain high-risk patients after chemotherapy.


11. Prognosis

The prognosis of MGUS is generally favorable. The annual rate of progression to multiple myeloma, WM, AL amyloidosis, lymphoma, etc. is about 1%, and even after 20 years only about 20% of patients progress (Mayo Clinic Kyle cohort, 2002). As a prognostic classification model, the Mayo Stratification for Myeloma and at Risk (MSmart) MGUS risk model, which uses M protein type (non-IgG > IgG), M protein concentration (≥1.5 g/dL), and an abnormal serum FLC ratio (< 0.26 or > 1.65) as risk factors, is used. The 20-year progression rate is about 5% in low-risk IgG MGUS, whereas it is about 58% in high-risk MGUS, a large difference.

The prognosis of essential thrombocythemia is generally very good. Median survival is about 18–20 years, and in young patients (≤60 years) it may be equal to or exceed normal life expectancy, reaching 35 years or more. The main causes of death are thrombotic complications (stroke, myocardial infarction, pulmonary embolism) and transformation to myelofibrosis or acute leukemia. After 20 years, the rate of transformation to myelofibrosis is about 5–10%, and the rate of transformation to acute leukemia (AML/MDS) is about 2–5%. Among molecular mutations affecting prognosis, MPL and CALR type 1 mutations are associated with an increased risk of MF transformation, and JAK2 V617F is associated with thrombotic risk.

The prognosis of primary myelofibrosis is the poorest among the D47 diseases. Risk classification according to DIPSS-plus (Dynamic International Prognostic Scoring System plus) or MIPSS70 (Mutation-Enhanced International Prognostic Score System for 70 years or younger) is used for treatment decisions. Median survival is about 15 years or more in the low-risk group, but only about 14–27 months in the high-risk group. The greater the number of high-risk mutations such as ASXL1, EZH2, IDH1/2, and SRSF2 (HMR, high-molecular-risk), the worse the prognosis. Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for PMF, but transplant-related mortality (TRM) and graft-versus-host disease (GVHD) limit the prognosis.

The prognosis of systemic mastocytosis differs sharply by subtype. In indolent SM (ISM), life expectancy is normal or near normal, and only about 5–10% of patients progress within 20 years. In contrast, median survival in aggressive SM (ASM) is about 3–5 years, and mast cell leukemia (MCL) has an extremely poor prognosis of several months to 1 year. Besides KIT D816V, the greater the number of high-risk co-mutations (SRSF2, ASXL1, RUNX1, TET2, etc., the so-called S/A/R/T mutations), the worse the prognosis. Since the introduction of avapritinib, survival outcomes in advanced SM have been improving markedly. Median survival in Waldenström macroglobulinemia is about 8–10 years, and risk is classified according to the International Prognostic Scoring System for WM (IPSSWM) (based on age, IgM level, β₂-microglobulin, hemoglobin, and platelet count). In the era of BTK inhibitor therapy, the 5-year survival rate is tending to improve to about 80% or higher. Richter transformation (transformation to aggressive lymphoma) occurs in about 2–5% and has a very poor prognosis.


12. Prevention

Most diseases in the D47 category occur sporadically, and the scope of primary prevention by eliminating known causative factors is limited. However, minimizing carcinogenic exposure and detecting precursor conditions early and following them appropriately are the key preventive strategies in managing this group of diseases.

In terms of minimizing carcinogenic exposure, limiting occupational exposure to benzene and aromatic organic solvents and using appropriate protective equipment may reduce the risk of developing MPN. Because smoking is associated with JAK2 V617F clonal expansion and the development of PV, smoking cessation is recommended. Avoiding unnecessary high-dose radiation exposure (e.g., radiotherapy for cancer treatment) and using the minimum effective dose when administering alkylating anticancer agents for treatment may lower the risk of secondary MPN.

In preventive management of MGUS, regular serologic follow-up is essential for patients diagnosed with MGUS even if they are asymptomatic. According to the long-term cohort study by Kyle et al. (2002), a 1% risk arises each year but persists indefinitely, so annual follow-up testing (SPEP, complete blood count, creatinine, calcium) is necessary even in low-risk MGUS. In high-risk MGUS, follow-up at 6-month intervals is recommended. For thrombosis prevention in ET patients, actively correcting cardiovascular risk factors (hypertension, diabetes, dyslipidemia, obesity, smoking) and maintaining low-dose aspirin are important for preventing thrombotic complications.

Prevention of anaphylaxis in patients with mastocytosis is central to preventing life-threatening complications. Patients are educated to avoid triggers that can induce mast cell degranulation (insect venoms such as bees and wasps; certain drugs — aspirin, NSAIDs, opioids, radiocontrast media, muscle relaxants) and to always carry an epinephrine autoinjector (EpiPen) in case of possible exposure. In patients with mastocytosis who are allergic to bee venom, venom immunotherapy (VIT) has been proven to significantly lower the risk of anaphylaxis, so its active use is recommended. Preoperative premedication (antihistamines, corticosteroids) minimizes the risk of intraoperative anaphylaxis. In WM patients, it is important to monitor serum IgM levels regularly and to consider early initiation of treatment to prevent hyperviscosity syndrome when IgM rises sharply.


13. References

  1. Tefferi A, Pardanani A. Essential Thrombocythemia: 2024 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2024;99(3):491–506. PMID: 38269572. DOI: 10.1002/ajh.27216
  2. Treon SP, Gustine J, Xu L, et al. Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2025;100(1):10–25. DOI: 10.1002/ajh.27666
  3. Reiter A, Gotlib J. Myeloid Neoplasms with Eosinophilia and Systemic Mastocytosis: 2023 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2023;98(3):401–416. PMID: 36606427. DOI: 10.1002/ajh.26852
  4. Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM. Myelofibrosis Treatment Algorithm 2018. Blood Cancer J. 2018;8(8):72. PMID: 30072688. DOI: 10.1038/s41408-018-0109-0
  5. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2006;354(13):1362–1369. PMID: 16571879. DOI: 10.1056/NEJMoa054494
  6. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. N Engl J Med. 2005;353(1):33–45. PMID: 16000354. DOI: 10.1056/NEJMoa043800
  7. DeAngelo DJ, Radia DH, George TI, et al. Safety and Efficacy of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis: Phase 2 PIONEER Trial. Nat Med. 2021;27(12):2183–2191. PMID: 34873357. DOI: 10.1038/s41591-021-01539-8
  8. Tam CS, Opat S, D'Sa S, et al. A Randomized Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Symptomatic Waldenström Macroglobulinemia: the ASPEN Study. Blood. 2020;136(18):2038–2050. PMID: 32556311. DOI: 10.1182/blood.2020006844
  9. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis (COMFORT-II). N Engl J Med. 2012;366(9):787–798. PMID: 22375970. DOI: 10.1056/NEJMoa1110556
  10. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. PMID: 24325359. DOI: 10.1056/NEJMoa1312542